Oncotelic Therapeutics, Inc. (OTLC) stock surged +0.25%, trading at $0.04 on PNK, up from the previous close of $0.04. The stock opened at $0.04, fluctuating between $0.04 and $0.04 in the recent session.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Employees | 22 |
Beta | -0.29 |
Sales or Revenue | $70.00K |
5Y Sales Change% | 66.82% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Oncotelic Therapeutics, Inc. (PNK: OTLC) stock price is $0.04 in the last trading session. During the trading session, OTLC stock reached the peak price of $0.04 while $0.04 was the lowest point it dropped to. The percentage change in OTLC stock occurred in the recent session was 0.25% while the dollar amount for the price change in OTLC stock was $0.00.
The PNK listed OTLC is part of Biotechnology industry that operates in the broader Healthcare sector. Oncotelic Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Steven W. King
Chairman, Pres & Chief Executive Officer
Mr. Burcak Beser
Chief Technology Officer of AI Division
Dr. Fatih M. Uckun M.D., Ph.D.
Chief Clinical Advisor & Consultant
Mr. Amit Shah
Vice President of Operations
Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D.
Chief Clinical Officer of Translational Medicine & Director
Mr. Saranjit Saund
CBO & GM of AI Division
Dr. Vuong Trieu Ph.D.
Chairman & Chief Executive Officer
Dr. Larn Hwang
Chief Scientific Officer
Dr. Seymour Howard Fein M.D.
Chief Regulatory Officer
Dr. Chulho Park Ph.D.
Consultant
OTLC's closing price is 290% higher than its 52-week low of $0.02 where as its distance from 52-week high of $0.04 is -22%.
Number of OTLC employees currently stands at 22.
Official Website of OTLC is: https://www.oncotelic.com
OTLC could be contacted at phone 650 635 7000 and can also be accessed through its website. OTLC operates from 29397 Agoura Road, Agoura Hills, CA 91301, United States.
OTLC stock volume for the day was 173K shares. The average number of OTLC shares traded daily for last 3 months was 171.11K.
The market value of OTLC currently stands at $16.29M with its latest stock price at $0.04 and 407.29M of its shares outstanding.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com